title: [Influence of Kurarinol on specific and non-specific cell immunity in patients with chronic hepatitis B].
abstract: OBJECTIVE
  To explore influence of Kurarinol on specific and non-specific cell immunity in patients with chronic hepatitis B.
  
  
  METHODS
  74 cases of CHB were randomly divided into two groups, 36 cases in treatment group, treated with 600 mg Kurarinol glucose injection, IV, once a day. After one month, Kurarinol capsule was used orally, three times a day for 2 months, 200 mg Silybin Meglumine Tablets orally, three times a day for 3 months. 38 cases in control group, only Silybin Meglumine Tablets was used, method and dosage were the same as treatment group. Compare HBV specific CTL, non-specific CTL, sub-group of T cells, changes of Th1 and Th2, negative conversion rate of HBV DNA and HBeAg of the two groups.
  
  
  RESULTS
  In treatment group, 3 months after treatment with Kurarinol, HBV specific CTL is higher than that before treatment (P < 0.01), it is also higher than that of control after treatment, P < 0.05) . Non-specific CTL is higher than that before treatment (P < 0.05), it is also higher than that of control after treatment (P < 0.01). CD4 is higher than that before treatment (P <0.05), it is also higher than that of control after treatment (P < 0.01), Thl is higher than that before treatment (P < 0.05), it is also higher than that of control after treatment (P < 0.01) . Negative conversion of HBV DNA and HBeAg is higher than that of control (P < 0.01).
  
  
  CONCLUSIONS
  Kurarinol can improve specific and non-specific cell immunity in patients with CHB. It is one of the mechanisms that Kurarinol can clear or inhibit HBV of patients with CHB.
authors.affiliation: Jiangsu Wuxi Hospital for Infectious Diseases, 214005, China. gxb188681@sina.com
authors.forename: Xi-Bing
authors.initials: XB
authors.lastname: Gu
authors.forename: Xiao-Juan
authors.initials: XJ
authors.lastname: Yang
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Yin-Fang
authors.initials: YF
authors.lastname: Zhu
authors.forename: Hong
authors.initials: H
authors.lastname: Ding
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.forename: Yue-Qin
authors.initials: YQ
authors.lastname: Xu
authors.forename: Hang-Yuan
authors.initials: HY
authors.lastname: Wu
mesh_terms: D000328:Adult; D004334:Drug Administration Schedule; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage*; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D000077385:Silybin; D012838:Silymarin / Q000008:administration & dosage; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D055815:Young Adult
chemical_list: D005419:Flavonoids; D012838:Silymarin; C526229:kurarinol; D000077385:Silybin